Should metformin be our antiglycemic agent of choice post-transplantation?

American Journal of Transplantation

Volumn 11, Issue 7, 2011, Pages 1376-1381

  Sharif, A ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease; malignancy; metabolic syndrome; Metformin; NODAT; obesity

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIOBESITY AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE; INSULIN SENSITIZING AGENT; METFORMIN; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PROTEIN KINASE LKB1;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; DIABETES MELLITUS; DIARRHEA; DRUG COST; DRUG MEGADOSE; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; EVIDENCE BASED PRACTICE; GLUCOSE METABOLISM; GRAFT RECIPIENT; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFLAMMATION; INSULIN RESISTANCE; MEGALOBLASTIC ANEMIA; METABOLIC SYNDROME X; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBESITY; ORGAN TRANSPLANTATION; POSTOPERATIVE PERIOD; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VALIDATION PROCESS; VOMITING; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; ANTICARCINOGENIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIAL CELLS; FATTY LIVER; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METFORMIN; OBESITY; ORGAN TRANSPLANTATION;

EID: 79959841768     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03550.x     Document Type: Review

References (29)

1. Davidson J, Wilkinson A, Dantal J, et al,. New-onset diabetes after transplantation: 2003 International consensus guidelines. Proceedings of an international expert panel meeting. Barcelona, Spain, 19 February 2003. Transplantation 2003; 75 (Suppl 10): SS3-SS24.
2. Kurian B, Joshi R, Helmuth A,. Effectiveness and long-term safety of thiazolidinediones and metformin in renal transplant recipients. Endocr Pract 2008; 14: 979-984.
3. American Diabetes Association. Standards of medical care in diabetes-2010. Diabet Care 2010; 33 (Suppl 1): S11-S61.
4. Grant PJ,. The effects of high- and medium-dose metformin therapy on cardiovascular risk factors in patients with type II diabetes. Diabet Care 1996; 19: 64-66.
5. Knowler WC, Barrett-Connor E, Fowler SE, et al,. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403. (Pubitemid 34437694)
6. Sharif A, Baboolal K,. Risk factors for new-onset diabetes after kidney transplantation. Nat Rev Nephrol 2010; 6: 415-423.
7. Potluri K, Hou S,. Obesity in kidney transplant recipients and candidates. Am J Kidney Dis 2010; 56: 143-156.
8. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D,. Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev 2005; CD002966.
9. Sharif A,. Metabolic syndrome and solid-organ transplantation. Am J Transplant 2010; 10: 12-17.
10. Bailey CJ, Turner RC,. Metformin. N Engl J Med 1996; 334: 574-579. (Pubitemid 126537875)
11. Carter AM, Bennett CE, Bostock JA, Grant PJ,. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with type 2 diabetes mellitus. Diabet Med 2005; 22: 1282-1284. (Pubitemid 41224195)
12. Haffner S, Temprosa M, Crandall J, et al,. Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes 2005; 54: 1566-1572.
13. Heilman RL, Devarapalli Y, Chakkera HA, et al,. Impact of subclinical inflammation on the development of interstitial fibrosis and tubular atrophy in kidney transplant recipients. Am J Transplant 2010; 10: 563-570.
14. De Jager J, Kooy A, Lehert P, et al,. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J Intern Med 2005; 257: 100-109. (Pubitemid 40129131)
15. Dureja P, Mellinger J, Agni R, et al,. NAFLD recurrence in liver transplant recipients. Transplantation 2011; 91: 684-689.
16. Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F,. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database Syst Rev 2007; CD005166.
17. Wulffele MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT,. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J Intern Med 2004; 256: 1-14. (Pubitemid 38813614)
18. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 854-865.
19. Buell JF, Gross TG, Woodle ES,. Malignancy after transplantation. Transplantation 2005; 80 (Suppl 2): S254-S264. (Pubitemid 41552912)
20. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD,. Metformin and reduced risk of cancer in diabetic patients. Bmj 2005; 330: 1304-1305. (Pubitemid 40813563)
21. Bowker SL, Majumdar SR, Veugelers P, Johnson JA,. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabet Care 2006; 29: 254-258. (Pubitemid 44106500)
22. Baas AF, Smit L, Clevers H,. LKB1 tumor suppressor protein: PAR taker in cell polarity. Trends Cell Biol 2004; 14: 312-319. (Pubitemid 38798180)
23. Shaw RJ,. LKB1 and AMP-activated protein kinase control of mTOR signalling and growth. Acta Physiol (Oxf) 2009; 196: 65-80.
24. Herman WH, Hoerger TJ, Brandle M, et al,. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 2005; 142: 323-332. (Pubitemid 40293405)
25. Sharif A, Moore R, Baboolal K,. Influence of lifestyle modification in renal transplant recipients with postprandial hyperglycemia. Transplantation 2008; 85: 353-358. (Pubitemid 351322758)
26. Peters N, Jay N, Barraud D, et al,. Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008; 12: R149.
27. Holstein A, Stumvoll M,. Contraindications can damage your health-is metformin a case in point? Diabetologia 2005; 48: 2454-2459. (Pubitemid 41738207)
28. Shaw JS, Wilmot RL, Kilpatrick ES,. Establishing pragmatic estimated GFR thresholds to guide metformin prescribing. Diabet Med 2007; 24: 1160-1163. (Pubitemid 47437878)
29. Lalau JD, Lacroix C, Compagnon P, et al,. Role of metformin accumulation in metformin-associated lactic acidosis. Diabet Care 1995; 18: 779-784.